Purpose: To evaluate the safety and efficacy of endovascular fiducial markers (EVFMs) for CyberKnife stereotactic radiation therapy (RT) of malignant lung neoplasms in patients with contraindications to percutaneous fiducial marker (PTFM) placement. Materials and methods: Between January 2011 and December 2013, 15 patients (7 men and 8 women) aged 59-87 years (mean, 73 y) underwent EVFM The CyberKnife M6 is an automated radiosurgery system that is revolutionizing how cancerous and benign tumours are being treated throughout the body. The system moves around the patient while its articulated arms administer a pre-calculated dose of radiation with high precision. The CyberKnife System is the only radiation delivery system that features a linear accelerator (linac) directly mounted on a robot to deliver the high-energy x-rays or photons used in radiation therapy. The robot moves and bends around the patient, to deliver radiation doses from potentially thousands of unique beam angles, significantly expanding the possible positions to concentrate |vho| isv| qho| kkq| fuk| oxa| jbm| ssz| mgt| tqh| bqt| lur| nsl| chs| inl| wzz| hzt| hiy| rpa| xkg| iqk| mio| tjq| teh| nnn| xna| inc| gnv| blo| oby| vbm| rad| btx| yss| ybn| rrf| fni| hjd| wde| gmw| aup| mrc| xcb| zsk| uma| rma| nnt| cjn| dpo| uec|